The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

ILD occurring during combo therapy (e.g. adalimumab + methotrexate) (e.g. PMID 24626274) or in which Pneumocystis infection was not appropriately ruled out (e.g. PMID 25717268) have indeterminate causality and are not quoted here

Publications

Turíbio DDCQ, Oliveira FCS, Barreto SMF, Jabour TBF

Interstitial lung disease due to anti-TNF use in the treatment of psoriasis.

Anais brasileiros de dermatologia. 2021;96(4):447-450

Certain MC, Georges M, Beltramo G, Schenesse D, Mouillot P, Tankéré P, Bonniaud P

Adalimumab-induced interstitial pneumonia in patients with inflammatory bowel disease.

Respiratory medicine and research. 2020;78:100790

Aqsa A, Sharma D, Chalhoub M

Adalimumab induced interstitial lung disease.

Respiratory medicine case reports. 2020;29:101012

Phang KF, Teng GG, Teo LLS, Seet JE, Teoh CM, Teo FSW

A 67-Year-Old Man With Psoriatic Arthritis and New-Onset Dyspnea.

Chest. 2018;154(5):e127-e134

Alaee S, Jones Q

Case of drug-induced interstitial lung disease secondary to adalimumab.

BMJ case reports. 2018;2018

Kato M, Oiso N, Nozaki Y, Inoue A, Hosono Y, Funauchi M, Mimori T, Matsumura I, Kawada A

Antitumor necrosis factor alpha inhibitor-induced dermatomyositis and interstitial lung disease with anti-PL12 autoantibody: signs of antisynthetase syndrome.

The Journal of dermatology. 2014;41(11):1034-6

Abdallah T, Abdallah M, Saifan C, El Sayegh D, Chalhoub M, Sasso L

Hemidiaphragm paresis and granulomatous pneumonitis associated with adalimumab: a case report.

Heart & lung : the journal of critical care. 2014;43(1):84-6

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.

Modern rheumatology. 2012;22(4):498-508

Reid JD, Bressler B, English J

A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.

Canadian respiratory journal. 2011;18(5):262-4

Dascalu C, Mrejen-Shakin K, Bandagi S

Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2010;16(4):172-4

Yamazaki H, Isogai S, Sakurai T, Nagasaka K

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis.

Modern rheumatology. 2010;20(5):518-21

Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM

Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab.

Arthritis and rheumatism. 2006;55(1):157-9